Modelling and simulation in the development and regulatory review of medicines
Comments on new guidance invited until 31 January 2017
The European Medicines Agency (EMA) has published a draft guideline to support and guide the use of innovative modelling and simulation approaches that are currently being used during the development of medicines.
Click on this link for more information.
